SEARCH

SEARCH BY CITATION

Two reports in this issue describe a nomogram for predicting survival and a landmark analysis demonstrating the relation between 6-month and 9-month progression-free status and overall survival in patients with metastatic urothelial cancer. These 2 important tools will be used to improve future clinical trial design in patients with advanced urothelial cancer.